{"transactions":[{"id":4621805,"issuer":{"id":4432,"kind":"organization","name":"Mineralys Therapeutics, Inc.","symbol":"MLYS"},"owners":[{"id":37289,"kind":"person","name":"Karydas Daphne","position":1,"cik":"0001816952","reported_name":"Karydas Daphne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-09-17T21:41:13.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in 36 monthly installments beginning on October 13, 2023."}],"balance_after":35000,"derivative":{"exercise_price":12.02,"expiration_date":"2033-09-13","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001816952-26-000005","document":"wk-form4_1789681270.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1933414/000181695226000005/wk-form4_1789681270.xml","form_type":"4"}},{"id":4621804,"issuer":{"id":4432,"kind":"organization","name":"Mineralys Therapeutics, Inc.","symbol":"MLYS"},"owners":[{"id":37289,"kind":"person","name":"Karydas Daphne","position":1,"cik":"0001816952","reported_name":"Karydas Daphne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-17T21:41:13.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":3000,"price":28.58,"value":85740.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2025."}],"balance_after":6200,"source":{"system":"sec-edgar","filing":"0001816952-26-000005","document":"wk-form4_1789681270.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1933414/000181695226000005/wk-form4_1789681270.xml","form_type":"4"}},{"id":4621803,"issuer":{"id":4432,"kind":"organization","name":"Mineralys Therapeutics, Inc.","symbol":"MLYS"},"owners":[{"id":37289,"kind":"person","name":"Karydas Daphne","position":1,"cik":"0001816952","reported_name":"Karydas Daphne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-17T21:41:13.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":true,"shares":3000,"price":12.02,"value":36060.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2025."}],"balance_after":9200,"source":{"system":"sec-edgar","filing":"0001816952-26-000005","document":"wk-form4_1789681270.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1933414/000181695226000005/wk-form4_1789681270.xml","form_type":"4"}},{"id":734237,"issuer":{"id":4432,"kind":"organization","name":"Mineralys Therapeutics, Inc.","symbol":"MLYS"},"owners":[{"id":37289,"kind":"person","name":"Karydas Daphne","position":1,"cik":"0001816952","reported_name":"Karydas Daphne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-06-18T01:18:02.000Z","date":"2026-06-17","kind":"exercise","planned":true,"acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in 36 monthly installments beginning on October 13, 2023."}],"balance_after":38000,"derivative":{"exercise_price":12.02,"expiration_date":"2033-09-13","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001933414-26-000093","document":"wk-form4_1781745479.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1816952/000193341426000093/wk-form4_1781745479.xml","form_type":"4"}},{"id":734236,"issuer":{"id":4432,"kind":"organization","name":"Mineralys Therapeutics, Inc.","symbol":"MLYS"},"owners":[{"id":37289,"kind":"person","name":"Karydas Daphne","position":1,"cik":"0001816952","reported_name":"Karydas Daphne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-18T01:18:02.000Z","date":"2026-06-17","kind":"sale","planned":true,"acquired":false,"shares":3000,"price":25,"value":75000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025."}],"balance_after":6200,"source":{"system":"sec-edgar","filing":"0001933414-26-000093","document":"wk-form4_1781745479.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816952/000193341426000093/wk-form4_1781745479.xml","form_type":"4"}},{"id":734235,"issuer":{"id":4432,"kind":"organization","name":"Mineralys Therapeutics, Inc.","symbol":"MLYS"},"owners":[{"id":37289,"kind":"person","name":"Karydas Daphne","position":1,"cik":"0001816952","reported_name":"Karydas Daphne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-18T01:18:02.000Z","date":"2026-06-17","kind":"exercise","planned":true,"acquired":true,"shares":3000,"price":12.02,"value":36060.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025."}],"balance_after":9200,"source":{"system":"sec-edgar","filing":"0001933414-26-000093","document":"wk-form4_1781745479.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816952/000193341426000093/wk-form4_1781745479.xml","form_type":"4"}},{"id":758828,"issuer":{"id":4567,"kind":"organization","name":"COMPASS Pathways plc"},"owners":[{"id":37289,"kind":"person","name":"Karydas Daphne","position":1,"cik":"0001816952","reported_name":"Karydas Daphne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-05-29T21:31:43.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":21110,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2027."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":21110,"derivative":{"exercise_price":11.85,"exercise_date":"2027-05-27","expiration_date":"2036-05-26","underlying":"Ordinary Shares","underlying_shares":21110},"source":{"system":"sec-edgar","filing":"0001816952-26-000004","document":"wk-form4_1780090300.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816952/000181695226000004/wk-form4_1780090300.xml","form_type":"4"}},{"id":819770,"issuer":{"id":4432,"kind":"organization","name":"Mineralys Therapeutics, Inc.","symbol":"MLYS"},"owners":[{"id":37289,"kind":"person","name":"Karydas Daphne","position":1,"cik":"0001816952","reported_name":"Karydas Daphne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-04-02T22:53:07.000Z","date":"2026-03-31","kind":"exercise","planned":true,"acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in 36 monthly installments beginning on October 13, 2023."}],"balance_after":41000,"derivative":{"exercise_price":12.02,"expiration_date":"2033-09-13","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001816952-26-000002","document":"wk-form4_1775170385.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1816952/000181695226000002/wk-form4_1775170385.xml","form_type":"4"}},{"id":819769,"issuer":{"id":4432,"kind":"organization","name":"Mineralys Therapeutics, Inc.","symbol":"MLYS"},"owners":[{"id":37289,"kind":"person","name":"Karydas Daphne","position":1,"cik":"0001816952","reported_name":"Karydas Daphne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-02T22:53:07.000Z","date":"2026-03-31","kind":"sale","planned":true,"acquired":false,"shares":3000,"price":25,"value":75000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025."}],"balance_after":6200,"source":{"system":"sec-edgar","filing":"0001816952-26-000002","document":"wk-form4_1775170385.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816952/000181695226000002/wk-form4_1775170385.xml","form_type":"4"}},{"id":819768,"issuer":{"id":4432,"kind":"organization","name":"Mineralys Therapeutics, Inc.","symbol":"MLYS"},"owners":[{"id":37289,"kind":"person","name":"Karydas Daphne","position":1,"cik":"0001816952","reported_name":"Karydas Daphne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-02T22:53:07.000Z","date":"2026-03-31","kind":"exercise","planned":true,"acquired":true,"shares":3000,"price":12.02,"value":36060.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025."}],"balance_after":9200,"source":{"system":"sec-edgar","filing":"0001816952-26-000002","document":"wk-form4_1775170385.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816952/000181695226000002/wk-form4_1775170385.xml","form_type":"4"}},{"id":890821,"issuer":{"id":4432,"kind":"organization","name":"Mineralys Therapeutics, Inc.","symbol":"MLYS"},"owners":[{"id":37289,"kind":"person","name":"Karydas Daphne","position":1,"cik":"0001816952","reported_name":"Karydas Daphne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-02-21T00:47:24.000Z","date":"2026-02-19","kind":"grant","planned":false,"acquired":true,"shares":8300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in 12 substantially equal monthly installments following the date of grant."}],"balance_after":8300,"derivative":{"exercise_price":28.06,"expiration_date":"2036-02-19","underlying":"Common Stock","underlying_shares":8300},"source":{"system":"sec-edgar","filing":"0001933414-26-000042","document":"wk-form4_1771634842.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816952/000193341426000042/wk-form4_1771634842.xml","form_type":"4"}},{"id":890820,"issuer":{"id":4432,"kind":"organization","name":"Mineralys Therapeutics, Inc.","symbol":"MLYS"},"owners":[{"id":37289,"kind":"person","name":"Karydas Daphne","position":1,"cik":"0001816952","reported_name":"Karydas Daphne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-21T00:47:24.000Z","date":"2026-02-19","kind":"grant","planned":false,"acquired":true,"shares":6200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant."}],"balance_after":6200,"source":{"system":"sec-edgar","filing":"0001933414-26-000042","document":"wk-form4_1771634842.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816952/000193341426000042/wk-form4_1771634842.xml","form_type":"4"}},{"id":1000346,"issuer":{"id":4432,"kind":"organization","name":"Mineralys Therapeutics, Inc.","symbol":"MLYS"},"owners":[{"id":37289,"kind":"person","name":"Karydas Daphne","position":1,"cik":"0001816952","reported_name":"Karydas Daphne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-11-14T00:01:24.000Z","date":"2025-11-13","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests in 12 monthly installments following the date of grant."}],"balance_after":17900,"derivative":{"exercise_price":10.2,"expiration_date":"2035-02-13","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001933414-25-000150","document":"wk-form4_1763078481.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1816952/000193341425000150/wk-form4_1763078481.xml","form_type":"4"}},{"id":1000345,"issuer":{"id":4432,"kind":"organization","name":"Mineralys Therapeutics, Inc.","symbol":"MLYS"},"owners":[{"id":37289,"kind":"person","name":"Karydas Daphne","position":1,"cik":"0001816952","reported_name":"Karydas Daphne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-14T00:01:24.000Z","date":"2025-11-13","kind":"sale","planned":false,"acquired":false,"shares":4885,"price":46.3554,"value":226446.129,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.19 to $46.70. The Reporting Person undertakes to provide\nto the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nranges set forth in this footnote (2) to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001933414-25-000150","document":"wk-form4_1763078481.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1816952/000193341425000150/wk-form4_1763078481.xml","form_type":"4"}},{"id":1000344,"issuer":{"id":4432,"kind":"organization","name":"Mineralys Therapeutics, Inc.","symbol":"MLYS"},"owners":[{"id":37289,"kind":"person","name":"Karydas Daphne","position":1,"cik":"0001816952","reported_name":"Karydas Daphne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-14T00:01:24.000Z","date":"2025-11-13","kind":"sale","planned":false,"acquired":false,"shares":10115,"price":45.8083,"value":463350.9545,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.19 to $46.18. The Reporting Person undertakes to provide\nto the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the\nranges set forth in this footnote (1) to this Form 4."}],"balance_after":4885,"source":{"system":"sec-edgar","filing":"0001933414-25-000150","document":"wk-form4_1763078481.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816952/000193341425000150/wk-form4_1763078481.xml","form_type":"4"}},{"id":1000343,"issuer":{"id":4432,"kind":"organization","name":"Mineralys Therapeutics, Inc.","symbol":"MLYS"},"owners":[{"id":37289,"kind":"person","name":"Karydas Daphne","position":1,"cik":"0001816952","reported_name":"Karydas Daphne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-14T00:01:24.000Z","date":"2025-11-13","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":10.2,"value":153000.0,"ownership":{"direct":true},"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001933414-25-000150","document":"wk-form4_1763078481.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816952/000193341425000150/wk-form4_1763078481.xml","form_type":"4"}},{"id":1111865,"issuer":{"id":4567,"kind":"organization","name":"COMPASS Pathways plc"},"owners":[{"id":37289,"kind":"person","name":"Karydas Daphne","position":1,"cik":"0001816952","reported_name":"Karydas Daphne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2025-06-13T12:18:45.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2026."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":26000,"derivative":{"exercise_price":4.52,"exercise_date":"2026-06-12","expiration_date":"2035-06-11","underlying":"Ordinary Shares","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001816590-25-000071","document":"wk-form4_1749817118.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816952/000181659025000071/wk-form4_1749817118.xml","form_type":"4"}},{"id":1249814,"issuer":{"id":4432,"kind":"organization","name":"Mineralys Therapeutics, Inc.","symbol":"MLYS"},"owners":[{"id":37289,"kind":"person","name":"Karydas Daphne","position":1,"cik":"0001816952","reported_name":"Karydas Daphne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-02-24T23:58:41.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":32900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in 12 substantially equal monthly installments following the date of grant."}],"balance_after":32900,"derivative":{"exercise_price":10.2,"expiration_date":"2035-02-13","underlying":"Common Stock","underlying_shares":32900},"source":{"system":"sec-edgar","filing":"0001933414-25-000013","document":"wk-form4_1740441514.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816952/000193341425000013/wk-form4_1740441514.xml","form_type":"4"}},{"id":1503805,"issuer":{"id":4432,"kind":"organization","name":"Mineralys Therapeutics, Inc.","symbol":"MLYS"},"owners":[{"id":37289,"kind":"person","name":"Karydas Daphne","position":1,"cik":"0001816952","reported_name":"Karydas Daphne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2024-05-23T20:21:30.000Z","date":"2024-05-22","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award vests in 12 substantially equal monthly installments beginning on June 22, 2024. In the event that the next annual meeting of stockholders occurs prior to May 22, 2025, any remaining unvested portion of the stock option award will vest on the date of such meeting."}],"balance_after":22000,"derivative":{"exercise_price":12.52,"expiration_date":"2034-05-22","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001933414-24-000020","document":"wk-form4_1716495678.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816952/000193341424000020/wk-form4_1716495678.xml","form_type":"4"}},{"id":1519159,"issuer":{"id":4567,"kind":"organization","name":"COMPASS Pathways plc"},"owners":[{"id":37289,"kind":"person","name":"Karydas Daphne","position":1,"cik":"0001816952","reported_name":"Karydas Daphne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2024-05-13T10:44:00.000Z","date":"2024-05-09","kind":"grant","planned":false,"acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2025."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":26000,"derivative":{"exercise_price":8.54,"exercise_date":"2025-05-09","expiration_date":"2034-05-08","underlying":"Ordinary Shares","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001816590-24-000095","document":"wk-form4_1715597030.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816952/000181659024000095/wk-form4_1715597030.xml","form_type":"4"}},{"id":1776296,"issuer":{"id":4567,"kind":"organization","name":"COMPASS Pathways plc"},"owners":[{"id":37289,"kind":"person","name":"Karydas Daphne","position":1,"cik":"0001816952","reported_name":"Karydas Daphne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2023-09-20T22:58:23.000Z","date":"2023-09-18","kind":"grant","planned":false,"acquired":true,"shares":52000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The share option vests in equal monthly installments over three years, with the first vesting on October 18, 2023."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":52000,"derivative":{"exercise_price":9.07,"exercise_date":"2023-10-18","expiration_date":"2033-09-17","underlying":"Ordinary Shares","underlying_shares":52000},"source":{"system":"sec-edgar","filing":"0001816952-23-000005","document":"wk-form4_1695250693.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816952/000181695223000005/wk-form4_1695250693.xml","form_type":"4"}},{"id":1781116,"issuer":{"id":4432,"kind":"organization","name":"Mineralys Therapeutics, Inc.","symbol":"MLYS"},"owners":[{"id":37289,"kind":"person","name":"Karydas Daphne","position":1,"cik":"0001816952","reported_name":"Karydas Daphne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2023-09-14T20:13:53.000Z","date":"2023-09-13","kind":"grant","planned":false,"acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in 36 monthly installments beginning on October 13, 2023."}],"balance_after":44000,"derivative":{"exercise_price":12.02,"expiration_date":"2033-09-13","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001933414-23-000079","document":"wf-form4_169472241630395.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816952/000193341423000079/wf-form4_169472241630395.xml","form_type":"4"}},{"id":2112368,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":37289,"kind":"person","name":"Karydas Daphne","position":1,"cik":"0001816952","reported_name":"Karydas Daphne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-11-18T02:07:29.000Z","date":"2022-11-16","kind":"disposition_to_issuer","acquired":false,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated as of October 3, 2022, by and among the Company, Alexion Pharmaceuticals, Inc. (\"Parent\") and Camelot Merger Sub, Inc. (\"Merger Sub\"), on November 16, 2022 (the \"Effective Time\"), Merger Sub merged with and into the Company (the \"Merger\"), with the Company continuing as the surviving corporation in the Merger and as a wholly-owned subsidiary of Parent, and, at the Effective Time, each option was cancelled pursuant to the terms of the Merger Agreement; provided, that each option with a per share exercise price equal to or greater than $2.07 was automatically cancelled for no consideration. For more information see the Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company with the United States Securities and Exchange Commission on October 18, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on June 17, 2022. The options were scheduled to vest in full on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the 2023 Annual Meeting of Stockholders of LogicBio Therapeutics, Inc.(the \"Company'), subject to the Reporting Person's continued service with the Company on the vesting date."}],"balance_after":0,"derivative":{"exercise_price":0.38,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0000899243-22-036295","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816952/000089924322036295/doc4.xml","form_type":"4"}},{"id":2214951,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":37289,"kind":"person","name":"Karydas Daphne","position":1,"cik":"0001816952","reported_name":"Karydas Daphne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-07-05T10:59:30.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The options were granted by LogicBio Therapeutics, Inc. (the \"Company\") pursuant to its 2018 Equity Incentive Plan, as provided under the Company's current non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest in full on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the Company's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service with the Company on the vesting date."}],"balance_after":12500,"derivative":{"exercise_price":0.38,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-22-040376","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816952/000120919122040376/doc4.xml","form_type":"4"}},{"id":2670419,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":37289,"kind":"person","name":"Karydas Daphne","position":1,"cik":"0001816952","reported_name":"Karydas Daphne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-15T00:00:52.000Z","date":"2021-06-11","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted by the Issuer pursuant to its 2018 Equity Incentive Plan as provided under the Company's compensation policy for non-employee directors. All of the options will vest and become exercisable on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the Company's 2022 annual meeting of stockholders, subject to the Reporting Person's continuous service with the Issuer through the vesting date."}],"balance_after":12500,"derivative":{"exercise_price":4.59,"expiration_date":"2031-06-11","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-21-040427","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816952/000120919121040427/doc4.xml","form_type":"4"}},{"id":2876905,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":37289,"kind":"person","name":"Karydas Daphne","position":1,"cik":"0001816952","reported_name":"Karydas Daphne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-05T21:22:19.000Z","date":"2021-02-03","kind":"grant","acquired":true,"shares":95000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option shall vest monthly over a four-year period."}],"balance_after":95000,"derivative":{"exercise_price":21.36,"expiration_date":"2031-02-03","underlying":"Common Stock","underlying_shares":95000},"source":{"system":"sec-edgar","filing":"0001562180-21-000933","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816952/000156218021000933/primarydocument.xml","form_type":"4"}},{"id":2946870,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":37289,"kind":"person","name":"Karydas Daphne","position":1,"cik":"0001816952","reported_name":"Karydas Daphne","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-12-14T21:46:50.000Z","date":"2020-12-10","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable in equal installments on each of the first three anniversaries of the grant date, December 10, 2020."}],"balance_after":20000,"derivative":{"exercise_price":7.36,"expiration_date":"2030-12-10","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-20-033748","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816952/000089924320033748/doc4.xml","form_type":"4"}}]}